MA
MCID: MGR028
MIFTS: 70

Migraine with or Without Aura 1 (MA)

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine with or Without Aura 1

MalaCards integrated aliases for Migraine with or Without Aura 1:

Name: Migraine with or Without Aura 1 57
Migraine 57 12 75 25 54 29 55 6 43 15 63 40 33
Migraine Disorder 12 25 17
Migraine with or Without Aura, Susceptibility to, 1 57 13
Migraine Disorders 44 72
Migraine Variant 12 72
Common Migraine 25 55
Migraine with or Without Aura 12
Headache Including Migraine 55
Migraine, Susceptibility to 6
Headache Migrainous 25
Disorder, Migraine 25
Headache Migraine 25
Migraine Headache 25
Migraine Syndrome 25
Classic Migraine 25
Migraines 25
Mgau; Ma 57
Mgr1 57
Mgau 57
Ma 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
headache duration 4-72 hours
aggravated by physical activity
genetic heterogeneity, see, e.g., mgr2 (), mgr3 (), mgr4 (), mgr5 (), mgr6 ()


HPO:

32
migraine with or without aura 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:6364
OMIM 57 157300
ICD9CM 35 346 346.9
MeSH 44 D008881
NCIt 50 C89715
SNOMED-CT 68 37796009
MedGen 42 C3887485
UMLS 72 C0042331 C0149931

Summaries for Migraine with or Without Aura 1

MedlinePlus : 43 What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine, including Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often) Certain foods and food additives such as Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats Who is at risk for migraines? About 12 percent of Americans get migraines. They can affect anyone, but you are more likely to have them if you Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy. What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine. Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day. Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will Take your medical history Ask about your symptoms Do a physical and neurological exam An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Migraine with or Without Aura 1, also known as migraine, is related to familial hemiplegic migraine and migraine without aura, and has symptoms including seizures, tremor and back pain. An important gene associated with Migraine with or Without Aura 1 is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are Taste transduction and Thyroid hormone signaling pathway. The drugs Timolol and Milnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are photophobia and vomiting

Disease Ontology : 12 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing.

Genetics Home Reference : 25 A migraine is a type of headache that typically causes intense, throbbing pain usually in one area of the head. People can experience migraines once a year to multiple times a week. A person is considered to have chronic migraines if they experience 15 or more headache days a month with eight of those days involving migraine headaches. Migraines typically first start during a person's teens to early twenties, but they can begin anytime from early childhood to late-adulthood. A migraine usually has three stages: the period leading up to the headache (known as the premonitory or prodromal phase), the migraine itself (the headache phase), and the period following the headache (known as the postdromal phase). The premonitory phase can start from several hours up to several days before the headache appears. In this phase, affected individuals can experience extreme tiredness (fatigue), concentration problems, and muscle stiffness in the neck. A wide variety of additional signs and symptoms can occur including excessive yawning, food cravings, irritability, depression, sensitivity to light, and nausea. About one-third of people with migraine experience a temporary pattern of neurological symptoms called an aura. An aura typically develops gradually over a few minutes and lasts between 5 and 60 minutes. Auras commonly include temporary visual changes such as blind spots (scotomas), flashing lights, and zig-zagging lines of color. Additional features of aura can include numbness, difficulty with speech and language, episodes of extreme dizziness (vertigo), and double vision. During an aura, affected individuals might experience abnormal sensations including tingling or numbness, usually of the hands or mouth. An aura usually starts within one hour of the start of a migraine. In some cases, an aura can occur without a subsequent migraine. In the headache phase, the pain may last from a few hours to a few days. Affected individuals tend to experience nausea, vomiting, dizziness, and sensitivity to light and sound in addition to headache. Some have changes in their vision or sensitivity to odors and touch. The postdromal phase usually lasts a few hours but can linger for more than a day. In this phase, the headache pain is gone but individuals can experience fatigue, drowsiness, decreased energy, concentration problems, irritability, nausea, or sensitivity to light. Affected individuals may also have brief episodes of head pain when moving their head. People with migraine, particularly women who have migraine with aura, have an increased risk of a type of stroke that is caused by a lack of blood flow to the brain (ischemic stroke), but this is a rare occurrence. There are many migraine disorders that usually include additional signs and symptoms. For example, familial hemiplegic migraine and sporadic hemiplegic migraine are characterized by migraine with associated temporary weakness that affects one side of the body (hemiparesis). Additionally, cyclic vomiting syndrome is a migraine disorder usually found in children that causes episodes of nausea and vomiting in addition to headaches.

OMIM : 57 Migraine is the most common type of chronic, episodic headache, as summarized by Featherstone (1985). One locus for migraine with or without aura (MGR1) has been identified on chromosome 4q24. Other loci for migraine have been identified on 6p21.1-p12.2 (MGR3; 607498), 14q21.2-q22.3 (MGR4; 607501), 19p13 (MGR5; 607508), 1q31 (MGR6; 607516), 15q11-q13 (MGR7; 609179), 5q21 (with or without aura, MGR8, 609570; with aura, MGR9, 609670), 17p13 (MGR10; 610208), 18q12 (MGR11; 610209), 10q22-q23 (MGR12; 611706), and the X chromosome (MGR2; 300125). Mutation in the KCNK18 gene (613655) on chromosome 10q25 causes migraine with aura (MGR13; 613656). A subtype of autosomal dominant migraine with aura (MA), familial hemiplegic migraine (FHM; see 141500), is caused by mutation in the CACNA1A gene (601011) on chromosome 19p13 (FHM1; 141500), by mutation in the ATP1A2 gene (182340) on chromosome 1q21 (FHM2; 602481), or by mutation in the SCN1A gene (182389) on chromosome 2q24 (FHM3; 609634). Another locus for FHM has been mapped to chromosome 1q31 (FHM4; see 607516). There is evidence that a polymorphism in the estrogen receptor gene (ESR1; 133430.0005) and a polymorphism in the TNF gene (191160.0004) may confer susceptibility to migraine. A polymorphism in the endothelin receptor type A gene (EDNRA; 131243.0001) may confer resistance to migraine. (157300)

NINDS : 54 The pain of a migraine headache is often described as an intense pulsing or throbbing pain in one area of the head. However, it is much more; the International Headache Society diagnoses a migraine by its pain and number of attacks (at least 5, lasting 4-72 hours if untreated), and additional symptoms including nausea and/or vomiting, or sensitivity to both light and sound. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. Roughly one-third of affected individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, anxiety, hormonal changes, bright or flashing lights, lack of food or sleep, and dietary substances.  Migraine in some women may relate to changes in hormones and hormonal levels during their menstrual cycle.  For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine has a genetic cause.

PubMed Health : 63 About migraine: Migraine is not the same as the usual kind of headaches that most people have every now and then. A migraine attack starts suddenly with severe pain on only one side of your head. The pain is much worse than a normal headache and usually accompanied by other symptoms as well. But these headaches are only considered to be migraines if the typical symptoms have occurred at least five times. Migraines can greatly affect everyday life. Some people only get them occasionally, while others are knocked out by migraines on several days every month. Different types of medicine can help you cope with migraines.

Wikipedia : 75 A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to... more...

Related Diseases for Migraine with or Without Aura 1

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine with or Without Aura 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1261)
# Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 35.7 SCN1A NOTCH3 CALCA CACNA1A ATP1A2
2 migraine without aura 35.5 SCN1A CACNA1A ATP1A2
3 sporadic hemiplegic migraine 35.5 SCN1A CACNA1A ATP1A2
4 hemiplegic migraine 35.2 SCN1A NOTCH3 MGR6 MGR5 CALCA CACNA1A
5 familial or sporadic hemiplegic migraine 35.0 SCN1A CACNA1A ATP1A2
6 cluster headache 33.5 CALCA CACNA1A
7 migraine with aura 33.5 SCN1A NOTCH3 EDNRA CACNA1A ATP1A2
8 hemiplegia 32.3 SCN1A CALCA CACNA1A ATP1A2
9 alternating hemiplegia of childhood 31.8 CALCA CACNA1A ATP1A2
10 nervous system disease 31.4 TNF SCN1A CACNA1A
11 constipation 31.2 PPOX HTR3A CALCA
12 headache 30.9 SCN1A EDNRA CACNA1A ATP1A2
13 breast adenocarcinoma 30.8 TNF ESR1 CALCA
14 premature ejaculation 30.5 HTR3A HTR1B
15 migraine, familial hemiplegic, 2 12.8
16 migraine, familial hemiplegic, 1 12.8
17 migraine, familial hemiplegic, 3 12.8
18 migraine with or without aura 13 12.7
19 migraine with brainstem aura 12.6
20 migraine with or without aura 8 12.4
21 migraine with or without aura 2 12.4
22 migraine with or without aura 12 12.4
23 migraine with aura 7 12.3
24 migraine with or without aura 6 12.3
25 migraine without aura 4 12.3
26 migraine with or without aura 10 12.3
27 migraine with or without aura 3 12.3
28 migraine with aura 9 12.3
29 migraine with or without aura 11 12.3
30 cyclic vomiting syndrome 12.2
31 mccune-albright syndrome 12.2
32 meconium aspiration syndrome 12.1
33 epilepsy, familial temporal lobe, 4 12.0
34 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.7
35 handl syndrome 11.7
36 vasculopathy, retinal, with cerebral leukodystrophy 11.7
37 trochleitis 11.6
38 macrophage activation syndrome 11.6
39 episodic ataxia 11.5
40 hemicrania continua 11.5
41 fibrous dysplasia/mccune-albright syndrome 11.5
42 visual snow syndrome 11.5
43 sturge-weber syndrome 11.5
44 convulsions, familial infantile, with paroxysmal choreoathetosis 11.5
45 alternating hemiplegia of childhood 1 11.5
46 carotidynia 11.5
47 fibromyalgia 11.4
48 vitamin b12-responsive methylmalonic acidemia 11.4
49 episodic ataxia, type 2 11.4
50 orthostatic intolerance 11.4

Comorbidity relations with Migraine with or Without Aura 1 via Phenotypic Disease Network (PDN):


Anxiety Esophagitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with or Without Aura 1:



Diseases related to Migraine with or Without Aura 1

Symptoms & Phenotypes for Migraine with or Without Aura 1

Human phenotypes related to Migraine with or Without Aura 1:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 photophobia 32 HP:0000613
2 vomiting 32 HP:0002013
3 phonophobia 32 HP:0002183
4 nausea 32 HP:0002018
5 migraine with aura 32 HP:0002077
6 migraine without aura 32 HP:0002083

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
photophobia
phonophobia
migraine with aura
migraine without aura
headache is unilateral
more
Abdomen Gastrointestinal:
vomiting
nausea

Clinical features from OMIM:

157300

UMLS symptoms related to Migraine with or Without Aura 1:


seizures, tremor, back pain, pain, headache, hemiplegia, syncope, nausea, chronic pain, recurrent paroxysmal headache, sciatica, vertigo/dizziness, sleeplessness, scotoma, scintillating, hemicrania

MGI Mouse Phenotypes related to Migraine with or Without Aura 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.17 ATP1A2 BRCA2 CACNA1A CLCN1 EDNRA ESR1
2 mortality/aging MP:0010768 10.1 ATP1A2 BRCA2 CACNA1A CLCN1 EDNRA ESR1
3 integument MP:0010771 10.02 ATP1A2 BRCA2 CACNA1A CLCN1 EDNRA ESR1
4 endocrine/exocrine gland MP:0005379 10.01 BRCA2 CACNA1A EDNRA ESR1 HTR1B HTR3A
5 muscle MP:0005369 9.91 ATP1A2 CACNA1A CLCN1 EDNRA ESR1 HTR1B
6 nervous system MP:0003631 9.85 ATP1A2 BRCA2 CACNA1A CLCN1 EDNRA ESR1
7 reproductive system MP:0005389 9.61 BRCA2 CACNA1A CLCN1 ESR1 HTR1B HTR3A
8 respiratory system MP:0005388 9.17 ATP1A2 CACNA1A EDNRA ESR1 NOTCH3 SCN1A

Drugs & Therapeutics for Migraine with or Without Aura 1

PubMed Health treatment related to Migraine with or Without Aura 1: 63

A lot of people who have migraines know from experience what helps them. This often involves lying down in a quiet and dark room and putting cool wet towels or cooling pads on the side of their head that hurts. Most people take medicine to get through attacks that are especially painful. Medications used for migraine attacks include, in particular, acetaminophen (paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid (the drug in medicines like Aspirin), diclofenac or ibuprofen, as well as special migraine medications like triptans. Acetaminophen (paracetamol), acetylsalicylic acid and ibuprofen are available without a prescription, as are two of the triptan drugs. But before using medication yourself it’s a good idea to see a doctor to find out if the headaches are actually migraines. Using painkillers and migraine medication too often can itself make the headaches worse. For this reason, people are advised not to take painkillers and migraine medications on more than ten days per month.

Drugs for Migraine with or Without Aura 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 562)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 4 26839-75-8 33624 5478
2
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
3
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
7
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
8
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
9
Dihydroergotamine Approved, Investigational Phase 4 6190-39-2, 511-12-6 10531
10
Frovatriptan Approved, Investigational Phase 4 158747-02-5 77992
11
Caffeine Approved Phase 4 58-08-2 2519
12
Eletriptan Approved, Investigational Phase 4 143322-58-1 77993
13
Almotriptan Approved, Investigational Phase 4 154323-57-6, 181183-52-8 123606
14
Nadolol Approved Phase 4 42200-33-9 39147
15
Dinoprostone Approved Phase 4 363-24-6 5280360
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Ticagrelor Approved Phase 4 274693-27-5 9871419
18
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
20
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
21
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
22
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
23
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
24
Oxcarbazepine Approved Phase 4 28721-07-5 34312
25
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
26
Lorazepam Approved Phase 4 846-49-1 3958
27
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
28
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
29
Ethanol Approved Phase 4 64-17-5 702
30
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
31
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
32
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
33
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
34
Donepezil Approved Phase 4 120014-06-4 3152
35
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
36
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
37
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
38
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
39
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
40
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
41
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
42
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
43
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
44
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
45
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
46
Memantine Approved, Investigational Phase 4 19982-08-2 4054
47
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
48
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
49 Erenumab Approved, Investigational Phase 4 1582205-90-0
50
Flunarizine Approved Phase 4 52468-60-7 941361

Interventional clinical trials:

(show top 50) (show all 1184)
# Name Status NCT ID Phase Drugs
1 Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines Unknown status NCT00363506 Phase 4
2 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
3 A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt Unknown status NCT02938182 Phase 4 clopidogrel
4 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo;Estradiol or Placebo
5 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
6 Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine Unknown status NCT02307071 Phase 4
7 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
8 Double-Blind, Placebo Controlled Trial of Greater Occipital Nerve Block for the Treatment of Migraine Attacks Unknown status NCT03159000 Phase 4 Saline
9 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
10 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
11 Randomized Controlled Trial Evaluating the Additive Value of Intranasal Fentanyl on Ibuprofen in the Pain Management of Children With Moderate to Severe Headaches Unknown status NCT02638506 Phase 4 Fentanyl
12 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
13 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
14 A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents Completed NCT01211145 Phase 4 Placebo;Zolmitriptan;Zolmitriptan;Zolmitriptan
15 Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting Completed NCT00364806 Phase 4 Prochlorperazine;Metoclopramide
16 Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly Completed NCT01450995 Phase 4 Treximet;Imitrex and two Aleve
17 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
18 A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS Completed NCT00634985 Phase 4 eletriptan
19 AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache Completed NCT00210509 Phase 4 almotriptan malate
20 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
21 Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study) Completed NCT00799045 Phase 4 Clopidogrel
22 Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults Completed NCT00792636 Phase 4 sumatriptan and naproxen sodium combination tablet;sumatriptan tablet;naproxen sodium tablet
23 A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years) Completed NCT02287376 Phase 4 Diclofenac Potassium for Oral Solution
24 Drug and Non-Drug Treatment of Severe Migraine Completed NCT00910689 Phase 4 Propranolol or nadolol;Placebo control;Optimal Acute Therapy
25 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
26 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Completed NCT00719134 Phase 4 Maxalt;placebo pill;placebo pills
27 An Open-label Study to Evaluate "Completeness of Response" Following Treatment With Treximet™ for Migraine Completed NCT00893737 Phase 4 sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
28 To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study. Completed NCT02035111 Phase 4 Tianshu capsule;Sugar pill
29 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
30 Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial Completed NCT02847494 Phase 4 metoclopramide;Dexamethasone;methylprednisolone acetate
31 A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan Completed NCT01086358 Phase 4 Triptan;Treximet 85Mg-500Mg Tablet
32 Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine Headache in Emergency Department: Randomize Controlled Trial Completed NCT03145467 Phase 4 Paracetamol;Zolmitriptan
33 A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated. Completed NCT00637286 Phase 4 Zolmitriptan
34 A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain Completed NCT00297375 Phase 4 tramadol HCl/acetaminophen
35 An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine Completed NCT01578941 Phase 4
36 AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain Completed NCT00212823 Phase 4 almotriptan malate
37 A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans Completed NCT01016834 Phase 4 Sumatriptan
38 A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
39 Adequate Therapy of Topiramate in Migraine Completed NCT01060111 Phase 4 Topiramate Standard;Topiramate Slow;Propranolol booster
40 Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial. Completed NCT01825941 Phase 4 metoclopramide;diphenhydramine;placebo
41 Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine Completed NCT00904098 Phase 4 Frovatriptan;Usual Care
42 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
43 A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine Completed NCT00443352 Phase 4 duloxetine
44 Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours? Completed NCT00216736 Phase 4 Dexamethasone;placebo
45 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
46 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine Completed NCT02147561 Phase 4
47 A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED) Completed NCT00449787 Phase 4 Sumatriptan 100 mg;Naproxen
48 IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac Completed NCT01267864 Phase 4 Metoclopramide;Ketorolac;Valproate
49 Greater Occipital Nerve Block for Migraine Prophylaxis Completed NCT00915473 Phase 4 bupivicaine;normal saline;methylprednisolone;lidocaine
50 Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study) Completed NCT01807234 Phase 4 Ketorolac;Sumatriptan;Placebo

Search NIH Clinical Center for Migraine with or Without Aura 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylsalicylic acid
Almotriptan
Amitriptyline
Atenolol
Botulinum toxin type A
Candesartan cilexetil
Cyclizine
Cyproheptadine
Diclofenac
Dihydroergotamine
Eletriptan
Ergotamine
Flavin mononucleotide
Frovatriptan
Galcanezumab
Guanfacine
Ibuprofen
Ketoprofen
Ketorolac
Lisinopril
Magnesium citrate
Metoclopramide
Metoprolol
Nadolol
Naproxen
Nicardipine
Pizotifen
Propranolol
Riboflavin
Sumatriptan
Timolol
Tizanidine
Topiramate
Ubidecarenone
Valproic acid
Venlafaxine
Verapamil
Zolmitriptan

Cochrane evidence based reviews: migraine disorders

Genetic Tests for Migraine with or Without Aura 1

Genetic tests related to Migraine with or Without Aura 1:

# Genetic test Affiliating Genes
1 Migraine 29 EDNRA ESR1 TNF

Anatomical Context for Migraine with or Without Aura 1

MalaCards organs/tissues related to Migraine with or Without Aura 1:

41
Brain, Testes, Cortex, Eye, Endothelial, Heart, Trigeminal Ganglion

Publications for Migraine with or Without Aura 1

Articles related to Migraine with or Without Aura 1:

(show top 50) (show all 30016)
# Title Authors PMID Year
1
MTHFR T677 homozygosis influences the presence of aura in migraineurs. 9 38 8
15154859 2004
2
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. 9 38 8
15014183 2004
3
CGRP may play a causative role in migraine. 9 38 8
11993614 2002
4
The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. 9 38 8
11121176 2000
5
Genome-wide meta-analysis identifies new susceptibility loci for migraine. 38 8
23793025 2013
6
Spreading depression triggers headache by activating neuronal Panx1 channels. 38 8
23449592 2013
7
Shared genetic factors in migraine and depression: evidence from a genetic isolate. 38 8
20071666 2010
8
Trait components provide tools to dissect the genetic susceptibility of migraine. 38 8
16773568 2006
9
Familial risk of migraine: variation by proband age at onset and headache severity. 38 8
16476932 2006
10
Migraine and MTHFR C677T genotype in a population-based sample. 38 8
16365871 2006
11
Migraine with aura is a risk factor for unprovoked seizures in children. 38 8
16374824 2006
12
The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. 38 71
15133719 2004
13
Localization of a gene for migraine without aura to chromosome 4q21. 38 8
14513409 2003
14
Nuclear factor-kappaB as a molecular target for migraine therapy. 38 8
11921057 2002
15
A susceptibility locus for migraine with aura, on chromosome 4q24. 38 8
11836652 2002
16
Migraine without aura: a population-based twin study. 38 8
10514097 1999
17
Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. 38 8
9989627 1999
18
Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. 38 8
9259375 1997
19
Variation in migraine prevalence by race. 38 8
8710124 1996
20
Inheritance of migraine investigated by complex segregation analysis. 38 8
8522335 1995
21
Familial occurrence of migraine without aura and migraine with aura. 38 8
8392151 1993
22
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. 38 8
1727198 1992
23
Familial migraine in a Mexican population. 38 8
1608495 1992
24
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. 38 8
1699472 1990
25
Segregation analysis of migraine in 128 families. 38 8
3527442 1986
26
Migraine and muscle contraction headaches: a continuum. 38 8
4019180 1985
27
Biochemical predisposition to dietary migraine: the role of phenolsulphotransferase. 38 8
6343297 1983
28
Migraine in twins. 38 8
859128 1977
29
MIGRAINE AND HEREDITY. 38 8
14322314 1965
30
Familiar occurrence of migraine headache: a study of heredity. 38 8
13196752 1954
31
Fremanezumab for the preventive treatment of migraine in adults. 38 17
31220963 2019
32
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. 38 17
31291516 2019
33
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. 38 17
31159727 2019
34
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors. 8
2940961 1986
35
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 9 38
20518725 2010
36
Dopamine: what's new in migraine? 9 38
20164768 2010
37
What have we learnt from triggering migraine? 9 38
20173638 2010
38
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 9 38
19936882 2010
39
The PACAP receptor: a novel target for migraine treatment. 9 38
20430318 2010
40
CGRP receptor antagonism and migraine. 9 38
20430315 2010
41
Migraine and obesity: epidemiology, mechanisms, and implications. 9 38
19845784 2010
42
Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. 9 38
20188075 2010
43
Calcitonin gene-related peptide: A molecular link between obesity and migraine? 9 38
20369076 2010
44
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. 9 38
20368903 2010
45
Single nucleotide polymorphisms of the serotonin transporter gene in migraine--an association study. 9 38
19845785 2010
46
A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. 9 38
20080591 2010
47
Migraine models. 9 38
20336417 2010
48
Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. 9 38
19607849 2010
49
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. 9 38
19796656 2009
50
CGRP antagonists: hope for a new era in acute migraine treatment. 9 38
20120204 2009

Variations for Migraine with or Without Aura 1

ClinVar genetic disease variations for Migraine with or Without Aura 1:

6 (show all 16)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PPOX NM_001122764.3(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 1:161140885-161140885 1:161171095-161171095
2 CAPN3 ; SGCB NM_000070.3(CAPN3): c.550del (p.Thr184fs) deletion Pathogenic rs80338800 15:42680002-42680002 15:42387804-42387804
3 BRCA2 NM_000059.3(BRCA2): c.4936_4939del (p.Glu1646fs) deletion Pathogenic rs80359473 13:32913428-32913431 13:32339291-32339294
4 CLCN1 NM_000083.3(CLCN1): c.950G> A (p.Arg317Gln) single nucleotide variant Pathogenic/Likely pathogenic rs80356702 7:143027961-143027961 7:143330868-143330868
5 TAB2 NM_015093.5(TAB2): c.1039C> T (p.Arg347Ter) single nucleotide variant Likely pathogenic rs1057518422 6:149700090-149700090 6:149378954-149378954
6 NOTCH3 NM_000435.3(NOTCH3): c.1450T> G (p.Cys484Gly) single nucleotide variant Likely pathogenic rs1555728965 19:15299088-15299088 19:15188277-15188277
7 ESR1 ESR1, 594G-A single nucleotide variant risk factor
8 MYH6 NM_002471.3(MYH6): c.3195G> C (p.Gln1065His) single nucleotide variant Conflicting interpretations of pathogenicity rs267606904 14:23862177-23862177 14:23392968-23392968
9 DSP NM_004415.4(DSP): c.5218G> A (p.Glu1740Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs142885240 6:7581641-7581641 6:7581408-7581408
10 CAPN3 NM_000070.3(CAPN3): c.1746-20C> G single nucleotide variant Conflicting interpretations of pathogenicity rs201892814 15:42695919-42695919 15:42403721-42403721
11 CACNA1A NM_001127221.1(CACNA1A): c.4177G> A (p.Val1393Met) single nucleotide variant Conflicting interpretations of pathogenicity rs794727411 19:13372340-13372340 19:13261526-13261526
12 MYH6 NM_002471.3(MYH6): c.4594C> T (p.Arg1532Cys) single nucleotide variant Uncertain significance rs201827489 14:23856794-23856794 14:23387585-23387585
13 MAP2K2 NM_030662.3(MAP2K2): c.514A> G (p.Lys172Glu) single nucleotide variant Uncertain significance rs1413580671 19:4102388-4102388 19:4102390-4102390
14 SCN5A NM_000335.4(SCN5A): c.892G> A (p.Gly298Ser) single nucleotide variant Uncertain significance rs137854608 3:38651267-38651267 3:38609776-38609776
15 SLC2A1 NM_006516.3(SLC2A1): c.1407G> C (p.Gln469His) single nucleotide variant Uncertain significance rs201748668 1:43392784-43392784 1:42927113-42927113
16 STIM1 NM_003156.3(STIM1): c.1534T> A (p.Ser512Thr) single nucleotide variant Uncertain significance rs1554971682 11:4107766-4107766 11:4086536-4086536

Copy number variations for Migraine with or Without Aura 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39736 10 118956999 118969809 Copy number KCNK18 Migraine

Expression for Migraine with or Without Aura 1

Search GEO for disease gene expression data for Migraine with or Without Aura 1.

Pathways for Migraine with or Without Aura 1

Pathways related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.42 HTR3A HTR1B CACNA1A
2 11.21 NOTCH3 ESR1 ATP1A2
3 10.86 HTR3A HTR1B CACNA1A

GO Terms for Migraine with or Without Aura 1

Biological processes related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.85 SCN1A HTR3A CLCN1 CACNA1A ATP1A2
2 ion transmembrane transport GO:0034220 9.62 SCN1A HTR3A CLCN1 CACNA1A
3 regulation of membrane potential GO:0042391 9.58 SCN1A HTR3A CACNA1A
4 vasoconstriction GO:0042310 9.37 HTR1B EDNRA
5 G protein-coupled receptor internalization GO:0002031 9.26 HTR1B CALCA
6 neuronal action potential propagation GO:0019227 9.16 SCN1A CLCN1
7 response to pain GO:0048265 9.13 CACNA1A
8 regulation of blood pressure GO:0008217 9.13 EDNRA CALCA ATP1A2
9 positive regulation of cytosolic calcium ion concentration GO:0007204 8.92 ESR1 EDNRA CALCA CACNA1A

Molecular functions related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.62 HTR3A HTR1B

Sources for Migraine with or Without Aura 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....